Does Lithium Cause Hypercalcemia?
Yes, lithium therapy can cause hypercalcemia, occurring in approximately 3-4% of lithium-treated patients, which is significantly higher than the 0.5% prevalence in the general population. 1
Mechanism and Clinical Significance
Lithium induces hypercalcemia through two distinct mechanisms:
Acute effects (potentially reversible):
- Lithium acts on the calcium-sensing receptor (CaSR) pathway, shifting the set-point for calcium regulation
- This creates a biochemical picture similar to familial hypocalciuric hypercalcemia (FHH)
- The parathyroid glands require higher calcium levels to suppress PTH secretion 2
Chronic effects (permanent):
- Long-term lithium therapy causes structural changes in parathyroid glands
- Either unmasks subclinical parathyroid adenomas or initiates multiglandular hyperparathyroidism
- Results in a biochemical picture identical to primary hyperparathyroidism 2
- Notably, there is a 51.28% prevalence of multiglandular disease in lithium-associated hyperparathyroidism (LAH), which is much higher than typical primary hyperparathyroidism 1
Monitoring Requirements
The FDA drug label for lithium explicitly requires baseline and regular monitoring of serum calcium levels 3. The 2007 AACAP guidelines recommend baseline serum calcium assessment before initiating lithium therapy, with regular monitoring every 3-6 months 4.
Critical caveat: Despite guideline recommendations, calcium and PTH are insufficiently measured in clinical practice for lithium-treated patients 1. This represents a significant gap in care that increases patient morbidity.
Time Course and Risk Factors
Duration of lithium treatment directly correlates with:
- Development of hyperparathyroidism (p < 0.01)
- Development of hypercalcemia (p < 0.01) 5
Higher risk occurs with:
- Lithium blood levels > 0.8 mEq/L (associated with significantly lower GFR: 61.8 vs 77.6 mL/min, p = 0.0134) 5
- Longer treatment duration (years to decades)
Unusual Presentation
While most lithium-induced hypercalcemia occurs with elevated PTH, rare cases present with hypercalcemia and normal PTH levels, suggesting an additional unidentified mechanism beyond parathyroid involvement 6. This underscores the importance of checking calcium levels even when PTH appears normal.
Clinical Implications
The hypercalcemia can manifest with typical symptoms: polyuria, polydipsia, nausea, confusion, fatigue, and cognitive dysfunction 3. These symptoms may be mistakenly attributed to psychiatric illness or lithium toxicity rather than hypercalcemia, leading to delayed diagnosis.
Treatment options for established LAH include:
- Parathyroid surgery (definitive for multiglandular disease)
- Cinacalcet (calcimimetic agent)
- Lithium discontinuation (conflicting evidence; may resolve LAH in selected cases, but evidence is anecdotal) 1
The evidence consistently demonstrates that lithium causes hypercalcemia through both acute reversible effects and chronic permanent parathyroid changes, with a prevalence approximately 6-8 times higher than the general population.